Search

Displaying results 1401 - 1410 of 5384 in total
  1. Drug

    Agalsidase beta

    go.drugbank.com/drugs/DB00103
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

  2. Drug

    Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11001
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016
  3. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11047
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot Fluvirin 2015-2016
  4. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].

  5. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    [A230733] Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection. … Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight.

  6. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.

  7. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10602
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot Fluvirin 2015-2016
  8. Drug

    Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB10999
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit
  9. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.

  10. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] … Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance